You searched for "Ranibizumab"
Licence to save: a UK survey of anti-VEGF use for the eye
This comment article highlights the controversy that exists in the choice for anti-VEGF drugs used for treatment of macular oedema and wet age-related macular degeneration (AMD). Two existing licensed drugs for macular oedema are ranibizumab (Lucentis) and aflibercept (Eylea). A...Advances and developments in medical retina
The author provides an update on late breaking clinical trial results in neovascular age-related macular degeneration (nAMD) and presentations on diabetes management from the American Academy of Ophthalmology Retina Subspecialty Day, held during the Academy’s annual meeting in Chicago, October...
Effect of syringe-filling technique and risk for endophthalmitis after intravitreal injection of anti-VEGF agents
In this retrospective study the authors compare the risk for post-injection endophthalmitis between different anti-vascular endothelial growth factor (VEGF) agents and syringe preparation technique. This multicentre study included 197,402 injections. The drugs included in this study were three Anti-VEGF agents...
Treat and extend for PCV
This South Korean study investigated the efficacy of a treat and extend regimen (TER) using ranibizumab to treat polypoidal choroidal vasculopathy (PCV). Twenty-nine eyes were included in this retrospective case note review. Of these, five eyes had been treated with...
Management of diabetic macular oedema (DMO)
The authors present guidelines on current diagnostic and therapeutic procedures in the management of DMO. Fluorescein angiography (FA) and optical coherence tomography (OCT) are recommended before starting treatment to help diagnose and stage DMO, and can be repeated if there...Outcomes at 100 weeks from the LEAVO study of intravitreal anti-VEGF therapies for macular oedema secondary to central retinal vein occlusion
Royal College of Ophthalmologists Annual Congress 2019, Glasgow - First presented and discussed on Monday 20 May 2019, with a further presentation of results during Retina Subspecialty Day on Thursday 23 May 2019. Among patients with macular oedema secondary to...
Insights in resistant diabetic macular oedema
This article gives a bird’s eye review of the different modalities for the treatment of diabetic macular oedema (DME). The debut of anti-VEGFs has brought a paradigm shift in DME management. This treatment has now become a major breakthrough in...Neovascular AMD: fresh recommendations underline standards of best practice
The management of neovascular age-related macular degeneration (nAMD) has advanced dramatically over the past seven years, with the introduction of targeted new therapies that successfully maintain or improve vision in a majority of affected individuals. It’s a fast moving field,...
The natural history of treatment naïve choroidal neovascularisation (CNV) in geographic atrophy
The aim of this retrospective study is to assess the characteristics and natural history of quiescent CNV in geographic atrophy (GA) utilising multi-modal imaging. Case notes were reviewed of patients diagnosed with geographic atrophy between January 2010 and December 2016...
The effects of anti-VEGF therapy for NvAMD on retinal vasculature
This retrospective consecutive case series examined 54 eyes of 54 treatment-naïve neovascular age-related macular degeneration (N-AMD) patients. Thirty-three eyes received intravitreal aflibercept injections, and 21 eyes received intravitreal ranibizumab injections with unaffected fellow eyes (54 eyes) as controls. All image...
Atrophy and anti-VEGF
The aim of this study was to investigate treatment factors, along with ocular and systemic factors for their association with macular atrophy (MA) incidence in eyes with neovascular age-related macular degeneration (nAMD) treated with anti-VEGF aflibercept or ranibizumab according to...
